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Abstract 
Safaa Zahi R. Sader 
STRUCTURAL AND DYNAMIC ANALYSIS OF WILD AND SPLICE VARIANTS 
HUMAN µ-OPIOID RECEPTORS (G1 &G2) AND AMSACRINE RESISTANCE IN 
HUMAN TOPOISOMERASE II ALPHA MUTANTS  
2015-2016 
Dr. Chun Wu, Ph.D. 
Master of Science in Pharmaceutical Sciences 
Morphine prescribing is limited by its high addiction tendency and other serious 
effects. Recent animal’s biological studies on Mu 6TM splice variants, which mainly 
include G1, G2 and Mu3, supported a high safety and potency profiles of IBNtxA as 
potential alternative of Morphine. Nevertheless, there is no high-resolution structures of 
these 6TM variants, and the detailed structural features and dynamic characteristics of these 
splice variants remain elusive. We applied homology modeling and MD simulation to 
probe the structural, dynamic and ligand binding differences between the wild type (7TM) 
and two major truncated 6TM variants (G1 and G2). MD results underscored important 
structural and dynamic differences between these receptors as well as prioritized ligand 
affinity toward each receptor. The second project in this thesis involves in silico analysis 
of mutational basis of Amsacrine resistance. Both R487K and E571K mutations were 
studied. MD results indicated significant weakening of Amsacrine affinity in two mutants 
in a consistent manner with the previous biological degree of resistance of two mutants. 
Additionally, the intercalation loss and ligand ternary complex coordinate changes were 
also revealed by MD simulation as possible causes of resistance. 
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Chapter 1 
Introduction to Computational Drug Design 
 
Currently, developing new drug can cost  approximately US 1.0 -1.9 billion.(1) 
This cost mainly because the company need to synthesize and make thousands of 
compounds to find the desired hit compound. Computational drug design and molecular 
modelling offers enormous opportunity in pharmaceutical research due to precision and 
cost effectiveness of algorithms used in these methods. The recent burst in 
bioinformatics, genomics and structural information data had discovered plethora of new 
targets and ligands. Considering the rapidly emerging new diseases and the cost and 
effort imposed by traditional drug design and development, computational  tools can 
provide fast and reliable  prediction of the pharmacological properties pertaining to 
ligand and target.(2) 
Drug discovery process is research intensive, time consuming and required 
exorbitant funding resources. (2)Traditionally, the HTS is the widely used screening 
method used by pharmaceutical companies where compounds synthesized and screened 
against certain target via assay based tests. However, when it comes to testing millions of 
compounds and the fact that many hits get stalled during clinical trials due to poor 
pharmacokinetics profile or unwanted side effects, this traditional process becomes heavy 
financial burden endured by the company and the cost of this research often transferred to 
the patient. 
Computer aided drug design employs different methodologies to explore the 
biological processes and most importantly the ligand –protein binding. Some of methods 
involves Bioinformatics tools, which provides the sources of data, required to start 
computational jobs. For instance, homology modeling and sequence alignment of new 
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and existing targets is of pivotal importance in target validation and characterization. 
Other tools involve ligand –protein bind g energy determination and visualization which 
will be discussed in this chapter. 
1.1 Computational Methods Used in this Thesis 
 
1.1.1 Bioinformatics. Bioinformatics combines computer science, statistics and 
mathematics, to analyze and interpret biological data. It has several applications in drug 
design such as sequence alignment and analysis and homology modeling.  
1.1.2. Homology modeling and sequence alignment. This technique is 
extremely important in predicting the protein structure if the experimental X-ray 
crystallography is not available. Furthermore, it is useful in refining the experimental 
structure obtained through the crystallography or NMR to provide more precise structure 
coordinates that can be further used for docking and simulation. Example tool is Prime 
(Schrodinger) is a powerful and complete tool for generating accurate receptor models 
for structure based drug design. Another function of Prime is sequence alignment of two 
or multiple protein sequences and gives an accurate prediction of degree of homology 
between the sequences from different species. This is crucial in structural modelling of 
new target when desired specie’s crystal structure is only available for other species. For 
example modelling desired human receptor based on experimentally available crystal 
structure of Mouse receptor. 
1.1.3. Molecular docking. Considered is essential tool in computer aided drug 
design that aims to generate an accurate ligand-receptor complex structure especially 
when the crystal structure is not resolved. Successful protein-ligand docking depends on 
exhaustive exploration of space and effective scoring. Glide docking conducts complete 
3 
 
systematic search of conformational, orientational and positional space of the docked 
ligand as can be seen in (figure 1). 
 
 
 
 
Figure 1. (A) Definition of core and rotamer groups (B) Ligand diameter and center 
definitions (C) Glide docking “funnel”, showing the Glide docking hierarchy. 
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Applications. 
1. Ligand-protein complex construction. 
2. Binding affinity calculations. 
3. Drug discovery and lead optimization. 
4. Virtual high throughput screening. 
1.1.4 Binding energy calculations. In biological systems, ligands are 
continuously binding and dissociating from the proteins as indicated by the following 
chemical equation: 
P+L      P.L 
There are many methods to measure the ligand –protein binding affinity .Most or all 
depends on measuring the binding as function of concentration of ligand or protein. For 
example enzyme inhibition essays, Isothermal titration calorimetry (ITC) and other 
essays. The binding reaction can also be analyzed in thermodynamics terms involving 
free energy, enthalpy and entropy. For binding reaction at constant pressure, the 
standards Gibbs free energy is given by: 
∆Go = −RT ln KB  
 
Moreover, this energy change can be broken down into energetic and entropic terms as 
follow: 
 
∆G° = ∆H − T∆S° 
Since (H=E+PV) and P&V hardly change at biological systems: 
∆G° ≈ ∆E − T∆S 
∆E can be averaged over the range of molecular conformations that the free and bound 
molecules explore due to thermal motions. Thus, the energy can be broken into number of 
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contributions including, electrostatic interactions among charged and dipolar chemical 
groups, hydrophobic interactions and intrinsic energetics of rotable bonds. 
Developing an effective biding- free energy scoring function. 
(OPLS-AA)Force fields development and  parameterizations(3).Force field 
calculates the molecular system potential energy as a sum of individual energy terms: 
E = E covalent+ E noncovalent 
E covalent = E bond (Stretching) + E angle (Bending) + E (dihedral) 
E noncovalent = E electrostatic + E van der Wales 
 
Force filed based scoring function with implicit solvent (MM-GBSA). MM-
GBSA(4) stands for the Molecular Mechanics Generalized Born Surface Area. It is 
fastest force-field based energy calculation obtained from energy difference between 
complex and unbound ligand and protein. It combines the molecular mechanics terms 
from force field with the solvation energy terms (implicit solvent), however, it lacks 
the entropy term as follows: 
ΔG=ΔEMM1+ΔGsolv2 - ΔT. ΔS 
        =ΔEbat3 + ΔEvdW + ΔEcoul + ΔGsolv, p 
+ ΔGsolv, np    - T ΔS 
 
                                                          
1 ΔEMM: gas phase molecular mechanics energy 
2 ΔGsolv: polar and nonpolar terms 
3 Ebat: covalent energy (bonds, angle, torsion). 
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XP Glide docking and scoring.XP glide score (5)is a novel semi empirical scoring 
function that uses unique water desolvation energy terms. Furthermore, new protein-
ligand structural binding terms to enhance prediction. The scoring function and docking 
protocol were developed to reproduce the experimental binding affinities for asset of 198 
complexes (RMSD of 2.26 and 1.73 Kcal/mol) over all and well docked ligands 
respectively. 
XP Glide Score = ΔEcoul + ΔEvdW+Ebind +Epenalty 
Ebind=Ehyd_enclosure4 +Ehb_nn_motif5 +Ehb_cc_motif6 +EpI7 + 
Ehb_pair +Ephobic_pair 
Epenalty = Edesolv +Eligand_strain 
1.1.5 Molecular dynamic simulations. This is one of the principal tools in 
theoretical Biological activity. It measures time dependent interaction between biological 
molecules such as protein-protein ligand-protein and ligand-DNA.MD simulation 
generates information at the microscopic level including atomic positions and velocities. 
Thus, it helps to visualize the macroscopic properties of system via microscopic simulation. 
For example, to calculate changes in the binding free energy of a particular drug, or to 
examine the energetics and mechanisms of conformational change. 
Biological Applications includes: 
 Protein stability  
 Conformational changes  
 Protein folding 
                                                          
4 Ehyd_enclosure: hydrophobic Enclosure 
5 Ehb_nn_motif: is the hydrogen bonds neutral-neutral motifs 
6 Ehb_cc_motif: hydrogen bonds charged-charged motif 
7 Epi: pi stacking and pi-cation interactions 
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 Molecular recognition: protein, DNA membrane. 
 Ion transport 
 Drug design and structure determination of X-ray and NMR structures. 
 The molecular dynamics simulation method is based on Newton’s second law or the 
equation of motion, Fi=mi.ai .From a knowledge of the force on each atom, it is possible 
to determine the acceleration of each atom in the system. Integration of the equations of 
motion then yields a trajectory that describes the positions, velocities and accelerations of 
the particles as they vary with time. From this trajectory, the average values of properties 
can be determined. Once the positions and velocities of each atom are known, the state of 
the system can be predicted at any time in the future or the past. Molecular dynamics 
simulations can be time consuming and computationally expensive. However, computers 
are getting faster and cheaper. Simulations of solvated proteins are calculated up to the 
nanosecond time scale; however, simulations into the millisecond regime have been 
reported. 
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Chapter 2 
Structural and Dynamic Analysis of Wild and Splice Variants µ-Opioid Receptors 
in Complex with Morphine and IBNtxA by Homology Modeling, Docking and All 
Atoms Molecular Dynamic Simulation with Explicit Membrane 
2.1 Introduction 
 Opioid drugs are a critical class of medications to treat acute and chronic pain, a 
serious and costly public health issue (6-9). The prototypical opioid analgesic morphine 
(Fig. 1A) is on the WHO Model List of Essential Medicines, the most important 
medications needed in a basic health system. However, the safety and tolerability of 
opioid analgesics is severely restricted due to side effects including sedation, 
constipation, abuse liability and respiratory depression (10-14). The constipating effects 
(15) in particular are common with chronic opioid use and can be dose-limiting, resulting 
in inadequate pain relief (16), particularly in cancer pain management. Opioid misuse and 
abuse is currently recognized as a major public health emergency, often referred to as the 
“opioid epidemic” (17-19). Thus, based on the very large public health need for effective 
analgesics, and substantial limitations confronting current prescription opioids, there is 
pressing need for the development of novel opioid analgesics with more precisely 
targeted mechanisms of action. 
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Figure 2. Chemical structures of morphine and IBNtxA. 
 
 
 
Mu opioid receptor (MOR) are selectively activated by morphine, and most 
opioid analgesics exert their effects via MOR signaling (20). MOR is a member of the G-
protein coupled receptor (GPCR) family, which is the largest and most diverse group of 
membrane receptors, targets for a large proportion of drugs currently used in medicine. 
Structurally, GPCRs all contain seven transmembrane (TM) domains with an 
extracellular N-terminus and an intracellular C-terminus. Classically, once an agonist 
binds, a conformational change in the receptor activates the α subunit of G-protein, which 
exchanges GTP in place of GDP, causing the dissociation of the α subunit, the β+γ dimer, 
and the receptor. Agonist binding to MOR-1 (e.g., by morphine), a Gαi/o-coupled GPCR 
(21), induces suppression of adenylyl cyclase activity via the activated Gαi/o subunit, 
thereby reducing intracellular cyclic AMP (cAMP) concentrations. The free β+γ dimer 
can activate G protein-coupled inwardly rectifying potassium (GIRK) channels, altering 
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cell membrane potentials. Additionally, MOR-1 has a dissociable signaling mechanism 
via β-arrestin (22-26).  
Since the cloning of the MOR gene, Oprm1, multiple splice variants have been 
discovered. (27-31) The primary MOR variant, MOR-1, has been widely studied and its 
high-resolution crystal structure has been obtained (32). In MOR-1, the TM domains 
form a circular structure with the opioid-binding pocket located deep within the TM 
region of the receptor (Fig. 3). Oprm1 splice variants include a variety of 3’ and 5’ 
splicing modifications, with similar patterns seen across a wide range of species, 
including humans, rats, and mice (10). Three major sets of splice variants have been 
identified. The first set are classical full-length variants, with all 7 TM domains, in which 
3’ splicing leads to changes in only the tip of the intracellular tail; these modifications 
may play important role in biased agonism (33). Because the remainder of these full-
length variants is the same, including all 7 TM domains, they should contain nearly 
identical ligand-binding pockets. The second set of splice variants involves exon 
skipping, producing only final protein products that contain a single TM domain. 
Although these variants do not bind opioids directly, they help modulate opioid analgesia 
by increasing expression of the full-length 7 TM variants through a chaperone-like action 
(34). The final set of splice variants—and the focus of this research involves exon 11 and 
its promoter, located about 30 k bases upstream of exon 1. These variants include exon 
11 to the exclusion of exon 1, and thus are presumed to lack the first TM (TM1) domain 
that exon 1 encodes, resulting in a truncated N-terminus (Fig. 2). Due to this truncation, 
these MOR variants have been described as containing only 6 TM domains (35-37). 
Three MOR variants (G1/1K/Mu3) completely lack the putative TM1 sequence, while the 
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G2 variant retains only a small segment of the TM1 domain sequence. The complete or 
partial absence of TM1 may change the ligand-receptor interaction, and thus opioid 
analgesics. Indeed, the opioid analgesics profile of these truncated 6 TM/exon 11 
(6TM/E11) variants is quite different from the full-length MOR-1, providing a target for 
new agents with unique pharmacologic properties.  
 
 
 
 
Figure 3. Abbreviated sequences of human MOR-1 (hMOR-1) splicing variants. 
Transmembrane domains (TM1 and TM2) are highlighted in yellow. Residues 121-360 
are not shown, as they are identical for all variants (see supporting info). 
 
 
 
  Various MOR-1 knockout mice models have provided important insights into 
pharmacological profiles of the different spice variants (10). Two models in particular are 
valuable: one MOR-1 knockout targeting exon 1, but still expressing exon 11-containing 
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6 TM truncated variants (38), and an exon 11 knockout that lacks the 6TM variants 
without appreciable changes in the expression levels of the full-length variants (39). 
These two knockout models reveal different profiles of activity for different opioids 
(Table 1). Based on the results of these studies, the analgesic effects of morphine are 
totally dependent on the full-length MOR-1 and but unaffected by loss of the 6-TM 
variants. Alternatively, the experimental drug 3-iodobenzoyl-6-naltrexamide (IBNtxA; 
Fig. 1), a potent analgesic in wild-type mice (40), is unaffected by the loss of the full-
length MOR-1 splice variants (or delta and kappa1 receptors), but loss of the exon 11 
variants removes its activity. This indicates that IBNtxA activity is primarily mediated 
through its binding to 6TM/E11 MOR variants. Furthermore, IBNtxA is a potent 
analgesic with an unusual pharmacologic profile. It is not only 10-fold more potent than 
that of morphine (40,41), but also active in neuropathic/inflammatory pain models, which 
is unusual for opioids (10). This is particularly useful in cancer pain management since 
much of it is neuropathic in nature. Its adverse effect profile is also very attractive: 
IBNtxA shows limited respiratory depression, reduced gastrointestinal slowing, and no 
measurable abuse liability in a conditioned place preference experiment, and does not 
produce physical dependence with chronic administration. These results raise the hope 
that it might be possible to dissociate opioid analgesia from side effects and abuse 
liability. Thus, targeting 6TM variants may yield important new analgesics in the future. 
However, there is no high-resolution receptor/complex structure of the 6TM/E11 MOR 
variants with morphine/IBNtxA, and it is not clear how the receptor truncation alters the 
ligand binding properties of these receptors. In this study, we aim to decipher the 
13 
 
structural and dynamic differences between splice variants and wild type when binding to 
morphine and IBNtxA.  
 
 
 
Table 1 
 MOR-1 knockout mouse models and opioid analgesia. 
Properties Exon 1 knockout a Exon 11 knockout b 
Mu receptor   
  7 TM variants Lost Retained 
  6 TM variants Retained Lost 
Analgesia     
  Morphine Lost Retained 
  IBNtxA Retained Lost 
a Schuller et al. (38) b Pan et al. (39) 
 
 
 
We applied homology modeling and MD simulations to understand the how 
truncated and wild type receptors responded to Morphine and IBNtxA activations. Our 
model was based on crystal structure of Mu-receptor bound to Morphinan antagonist (2.8 
Å) as a template to construct the two splice variants G1 and G2 receptors as well as Mu 
receptor wild type . The final homologs were obtained from GPCR-I-TASSER server 
(42). Furthermore, we utilized Glide XP docking to dock Morphine and IBNtxA into wild 
type and splice variants. Using the complexes from Xp docking, we constructed six 
model systems of morphine and IBNtxA docked into three receptors and performed 100 
ns MD simulations using consistent conditions for all six complexes. Results of 2D 
interactions, protein Cα RMSFs and RMSDs data where supporting the premise that 
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morphine and IBNtxA have completely different binding pockets and each one activated 
its native wild type and related splice variant receptors differently. Predicted binding 
energy calculations showed Morphine prioritize its wild type Over G1 and G2 .On the 
other hand, IBNtxA showed higher affinity toward its wild type (G1) and 7TM compared 
to G2. The 2D interaction comparisons among the three receptors complexes provided 
additional evidence that splice variants interact with each ligand using different binding 
pocket as indicated by genetic numbering. Collectively, truncated splice variants 
responded differently from canonical Mu receptor, which provided new opportunities of 
developing safe and effective morphine alternatives as indicated by in vivo and 
computational results of G1 receptor modeling and IBNtxA pharmacological 
characterizations data. 
2.2 Computational Methods  
2.2.1 Homology modeling of receptors. The FASTA sequences files of hMOR-
1, hMOR-1G1 and hMOR-1G2 were obtained from the Uniprot website(43). GPCR-I-
TASSER online service(42)was used to build their homology models . Out of five 
homology models for each receptor obtained from the GPCR-I-TASSER online service, 
the top 1 model was used in this study. The following PDB structures were used as 
templates for building homology models by GPCR-I-TASSER: human delta opioid 7TM 
receptor (PDB ID: 4N6H), Mu-opioid receptor in complex with a Morphinan antagonist 
(PDB ID: 4DKL), chimeric protein of 5-HT1B-BRIL in complex with ergotamine (PDB 
ID: 4IAR) and human delta opioid 7TM receptor (PDB ID: 4N6H). 
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2.2.2 Glide docking.  
Ligand preparation. The 3D structure of morphine and IBNtxA were prepared 
using Maestro Elements. The 2D structures of morphine and IBNtxA were drawn using 
the 2D sketcher. Then after, the ionization/tautomeric states were generated at pH=7 
using the Epik which is based on the more accurate Hammett and Taft 
methodologies(44). Only lowest ionization/tautomeric states were selected. Restrained 
minimization was used to relax the ligand structure. 
Protein structure preparation. Protein structures were prepared using 
Schrodinger maestro protein preparation Wizard.(44) The charge state of preprocessed 
protein was optimized at pH=7. Finally restrained minimization was performed to relax 
the protein structure using OPLS3 force field (45).  
Ligand docking. The binding sites of the prepared receptors were identified using 
“binding site detection” module of Maestro. The site that is close to the N-terminal 
binding pocket was used for docking, and the prepared ligands were docked into the N-
terminal pocket using Glide XP scoring function with default procedures and parameters 
(5,46). In details, the receptor grid required for docking process was generated using Van 
der Waals scaling factor of 1 and partial charge cutoff 0.25. Docking was performed 
using a ligand-centered grid using OPLS3 force field.  Glide XP Dock performed a 
comprehensive systematic search for the best receptor conformations and orientations to 
fit the ligand. The docking results are included in Figure S2 of the supporting material. 
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2.2.3 Molecular dynamic simulations. All six molecular dynamic simulation 
systems were constructed using the prepared receptor-ligand complexes from the XP 
docking. Each system was placed in a membrane of POPC lipids (47), and solvated in an 
orthorhombic water box with a buffer distance of 8Å using SPC water model (48). 
System was neutralized using Na+ ions, and was added with a salt concentration of 0.15 
M NaCl.  OPLS3 force field (45)was used to represent the receptor-ligand.   
Relaxation and production runs. Using Desmond module, the system was first 
relaxed using the default relaxation protocol for membrane proteins  (49). This relaxation 
protocol consists of eight stages: 1). Minimization with restraints on solute heavy atoms; 
2) Minimization without any restraints; 3). Simulation with heating from 0 K to 300 K, 
H2O barrier and gradual restraining; 4). Simulation under the NPT ensemble (constant 
number of particles, constant pressure of 1 bar and constant temperature of 300 K, 
Martyna-Tuckerman-Klein Nosé-Hoover chain coupling scheme (50)with H2O barrier 
and with heavy atoms restrained; 5) Simulation under the NPT ensemble with 
equilibration of solvent and lipids; 6). Simulation under the NPT ensemble with protein 
heavy atoms annealing from 10.0 kcal/mol to 2.0 kcal/mol; 7). Simulation under the NPT 
ensemble with Ca atoms restrained at 2 kcal/mol; and 8). Simulation for 1.5 ns under the 
NPT ensemble with no restraints.  After the relaxation, a 100.0 ns production run was 
conducted under the NPT ensemble for each of the six systems using the default protocol.  
M-SHAKE (51)was applied to constrain all bonds connecting hydrogen atoms, enabling a 
2.0 fs time step in the simulations. The k-space Gaussian split Ewald method (52) was 
used to treat long-range electrostatic interactions under periodic boundary conditions 
(charge grid spacing of ~1.0 Å, and direct sum tolerance of 10–9). The cutoff distance for 
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short-range non-bonded interactions was 9 Å, with the long-range van der Waals 
interactions based on a uniform density approximation. To reduce the computation, non-
bonded forces were calculated using an r-RESPA integrator (53) where the short range 
forces were updated every step and the long range forces were updated every three steps. 
Temperature was controlled using the Martyna-Tuckerman-Klein Nosé-Hoover chain-
coupling scheme with a coupling constant of 1.0 ps. The trajectories were saved at 40.0 
ps intervals for analysis.  
Convergence of simulation. Convergence of simulation were inspected using the 
root mean square deviation (RMSD) of the protein Cα atoms as a measure of system 
equilibration. Protein RMSD is calculated as an average change of displacement of 
selection of atoms for particular frame with respect to particular frame relative to the 
initial frame structure. RMSD plots are shown in Figure S3 of the supporting material.   
Receptor-ligand interaction analysis. Detailed receptor-ligand interaction was 
analyzed using Simulation Interaction Diagram module of Maestro.  The results are 
included in Figure S7-S15 of the supporting material.  
Trajectory clustering analysis. Protein backbone RMSD matrix was used in 
hierarchical cluster average linkage method (54)to group the complex structures of the 
simulation trajectory for each system. The merging distance cutoff used was set to be 2Å.  
The centroid structure (i.e. the structure having the largest number of neighbors in the 
structural family) was used to represent the family. The centroid structures of populated 
structural families (>1% of total structure population) are shown in Figure S5-S6 of the 
supporting material. 
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2.2.4 Binding energy calculations and decompositions methods. Molecular 
Mechanism-General Born Surface Area (MM-GBSA) binding energies were calculated 
for frames of the last 20ns of trajectory. VSGB 2.0 with implicit membrane model (4) 
was used based on OPLS3 force field.  The stepwise energy calculations as follows: (1) 
Receptor alone (minimization). 
(2) Ligand alone (minimization).(3) Receptor-ligand complex (minimization) (4) Ligand 
extracted from optimized receptor-ligand complex (energy calculation)(5) Receptor 
extracted from optimized receptor-ligand complex (energy calculation) .MMGBSA 
binding energy decompositions in this study, we merge the original terms (Coulombic + 
H-bond + GB solvation+ van der Waals + pi-pi packing + self-contact + lipophilic)(55) 
into three components: Eelectrostatics, EvdW, and ELipophilic, where   Eelectrostatics=(Hbond + 
Ecoulomb +EGB_solvation), EvdW = (EvdW+Epi-pi +Eself-contact)  and Elipophilic. 
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2.3 Results  
2.3.1 Homology modelling. Using the X-ray solved complex structure of mouse 
MOR1 with a ligand (32), the homology models of the full length and truncated human 
MOR-1 were obtained. The cartoon representations are shown in (Figure 3) from top 
viewpoints. Clearly, the TM1 is completely missed in G1 receptor. It is interesting that 
TM1 in 1G2 is only partially missed, because the protein sequence encoded by exon 11 in 
hMOR-1G2 is predicted to be helical. However, this partial truncation should not change 
much the ligand interaction with hMOR-1G2 from that with 1G1/K1/Mu3, because the 
partially helix is located at intracellular part and not at extracellular part where ligands 
bind to. It appears that TM1 is next the binding pocket, and thus its action on ligand-
receptor interactions may come from indirect allosteric/chaperone-like effect. 
Nonetheless, the partial or complete missing of TM1 can significantly change ligand-
receptor interaction and dynamics, and thus changing the response of the receptors in 
comparison to full-length version. The differences provide the base for designing more 
selective ligands toward specific variant. These homology models can be good starting 
structures for long time scale (μs) convention and replica exchange molecular dynamics 
simulations to inspect these ligand-protein interaction and dynamics (56-61).  
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Figure 4. Homolog models of (A) full length 7TM hMOR-1 receptor, (B) truncated 
MOR-1G2 and (C) hMOR-1G1. 
 
 
 
2.3.2 XP Glide docking. In order to build the Mu receptors complexes with 
morphine and IBNtxA, we used Glide XP docking implemented in Schrodinger 
(methodology). Each ligand (IBNtxA and morphine) was docked into three receptors and 
binding poses were utilized as input structure to perform MD simulations. In addition, we 
recorded the XP scores to get initial insight into the binding affinities of each ligand to 
wild type and truncated variants (scores table is not shown). Morphine showed binding 
energy of (-3.4 kcal) to full-length hMOR-1 which is slightly stronger than its binding to 
the truncated G2 (-2.7 kcal/mol) and G1 (-3.0 kcal/mol). While the binding pose to the 
full-length hMOR-1 is similar to hMOR-1G2 with a partial truncation of TM1, its 
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binding pose is significantly different from its binding pose to hMOR-1G1 with a full 
truncation TM1. In contrast, IBNtxA binds more strongly to hMOR-G2 and hMOR-G1 
than to hMOR-1. The binding poses on hMOR-G2 and hMOR-G1 are different from its 
binding pose to hMOR-1. It is also clear the binding energy of IBNtxA on G2/G1 is 
stronger than the binding energy of morphine on the full-length hMOR1. 
    2.3.3 Ligand binding energy calculations.  To characterize ligand binding 
affinities toward different receptors , we performed   the MMGBSA calculation (4) as 
descripted in the method section and results are tabulated in (table 2).  Morphine binding 
to its wild type receptor 7TM showed ΔG of -73.6 kcal/mol compared to -66.4 kcal/mol 
and -54.9 kcal/mol in case of G2 and G1 respectively. The order is 7TM>G2>G1, 
morphine binds more favorable to 7TM than to G2 and G1 by -7.2 kcal/mol and -18.7 
kcal/mol respectively. In contrast, IBNtxA binding to its wild type (G1) receptor 
possessed the highest affinity (ΔG = -134.9 kcal) compared to -102.6/mol kcal and -118.9 
kcal/mol for G2 and 7TM receptors respectively. The order is G1>7TM>G2, IBNtxA 
binds more favorable to G1 than 7TM and G1 by -15.9 kcal/mol and -32.3 kcal/mol, 
respectively.  The ligand-receptor binding order from our MMGBSA binding energy data 
is consistent with that of our XP scores, except that IBNtxA binds stronger to 7TM than 
to G2.  Therefore, MMGBSA data generally supports our early speculation that the 
activity differences between morphine and IBNtxA might be caused by the differences in 
the binding affinity. Our decomposition results indicated that, with all six complexes, 
ΔVDW and ΔLIPO have the highest contribution compared to  
ΔGBELE.However,significant variations observed were as follows:(1)with 
Morphine,7TM has higher contribution from ΔVDW and ΔLIPO compared to  those in  
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G1 and G2 .Whereas in G2,ΔGBELE contribution was the highest. (2)With IBNtxA , 
ΔVDW and ΔLIPO contributions was proportionate in all three receptors .However, 
ΔGBELE contribution  in G1 was significantly higher than 7TM which in turn was 
higher than G2.These inter receptors variations in energy decomposition components can 
be utilized to design effective future G1 and G2 candidates .Above results are tabulated 
in table 2. 
 
 
 
 
Table 2 
MMGB-SA binding energies for both Morphine and IBNtxA complexes with the three 
receptors. 
 LIGAND Morphine IBNtxA 
RECEPTOR 7TM G2 G1 7TM G2 G1 
ΔG1 -73.6±4 -66.4±6.5 -54.9±5.3 -119.0±5.4 -102.6±4.6 -134.9±6.6 
ΔΔG2 0.0 7.2 18.7 15.9 32.3 0.0 
ΔVDW3 -35.9±1.6 -27.9±8.4 -28.6±2.2 -53.4±2.3 -49.5±2.7 -52.9±1.7 
ΔΔVDW 0.0 8.1 7.3 -0.5 3.4 0.0 
ΔGBELE4 -2.5±3.6 -8.7±4.5 -2.2±2.5 -13.2±3.8 -6.9±3 -27.9±3.8 
ΔΔGBELE 0.0 -6.2 0.3 14.7 21.1 0.0 
ΔLIPO5 -35.1±1.0 -29.8±3.2 -24.0±1.6 -52.4±2.8 -46.3±2.3 -54.1±3.1 
ΔΔLIPO 0.0 5.3 11.1 1.7 7.8 0.0 
1 ΔG: MM-GBSA binding energy (Complex − Receptor − Ligand). 
2 ΔΔG: relative binding energy with reference to active complex (wide type/G1). 
3 ΔVDW: Change of van der Waals energy (vdW + Pi-pi stacking +Self-contact correction) in gas phase 
upon complex formation 
4ΔGBELE: Change of electrostatic interactions (GB/Generalized Born electrostatic solvation energy+ 
ELE/Coulomb energy +Hydrogen-bonding) upon complex formation. 
5 Change of lipophilic term (Lipophilic energy) upon complex formation. 
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2.3.4 Morphine and IBNtxA binding poses. To identify the major binding pose, 
we clustered the trajectory (54) as described in the method section. The representative 
structure of the most abundance structure families are shown in Figure 4. Morphine 
binding to its wild type and two splice variants adopted three slightly different poses 
(Figure 4 A-C). IBNtxA binding to its wild type receptor and its splice variants structures 
(Figure 4 D-F) also showed three distinct binding poses. To facilitate the comparison, we 
superimpose the three complexes for the same ligand in Figure 5.  
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Figure 5. Superposition of the most abundant complexes from the simulations.  The 
yellow, purple and cyan colors refer to wild type, G1 and G2 respectively. 
 
 
 
2.3.5 Morphine and IBNtxA ligand 2D interaction data. To identify critical 
residues contributing to morphine and IBNtxA bindings in each receptor, we did the 
simulation interaction diagram analysis, which is implemented in DESMOND.  The raw 
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data are included in Figure S7-12 and the key interacting residues for each ligand were 
tabulated in Table 3. For example, morphine-7TM 2D interaction conferred 18 different 
residues from transmembranes 2, 3, 5, 6, and 7. Polar Residues are: ASP1162.50, 
ASP1493.32, , ASN1523.35, TYR1503.33 ,SER1563.39 , LYS2355.40  , TRP2956.48  , CYS2946.47 
HSD2996.52  CYS3237.37, TYR3287.42, TRP3207.34, , and hydrophobic residues: 
ALA1192.53, MET1533.36  VAL2385.43   , LE2986.51 ,VAL3026.55,  and ILE3247.38 . 
Morphine binding to other two splice variants confers slightly different binding residues 
compared to wild type. Similarly, IBNtxA binding to its wild type (G1) showed different 
residues contacting the ligand compared to wild type. Figure 5 shows residues contacting 
ligand more than 30% of simulation time. Clearly, we see there is no single interacting 
residue of 7TM, G1 and G2 is identical for morphine. For IBNtxA, TRP7.34 is conserved 
for 7TM and G2 and TYR7.42 is conserved for G2 and G1.   
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Table 3 
 Morphine 2D interaction table with three different receptors. The three receptors are 
aligned using Schrodinger maestro software, the genetic numbering was used to compare 
residues in different receptors. 
  Morphine     IBNtxA   
GEN_NO   7TM G2 G1 7TM G1 G2 
2x50 ASP116       
2x53 ALA119   ALA119    
2x57      LEU42 
2x60  GLN45 GLN26 GLN126 GLN26 GLN45 
2x64    TYR130 TYR30 TYR49 
e1    TRP135  TRP54 
3X28  VAL64      
3x29  ILE65  ILE146 ILE46 ILE65 
3x32 ASP149 ASP68 ASP49 ASP149 ASP49 ASP68 
3x33 TYR150 TYR69  TYR150 TYR50 TYR69 
e2  THR139      
3x35 ASN152 GLU150 ASN52 ASN152    
3x36 MET153  MET53 MET153 MET53 MET72 
3x37      PHE73 
3X39 SER156  SER56 ASP218    
E2     LEU121 THR139 
E2     PHE123 LEU140 
5X39    LEU234 LEU134   
5X36      GLU150  
5x40 LYS235 LYS154  LYS235  LYS154 
5x43 VAL238  PHE191 VAL238 VAL138 VAL157 
6x47 CYS294  CYS194     
6x48 TRP295  TRP195 TRP295 TRP195   
6x51 ILE298 ILE217 ILE198 ILE298 ILE198 ILE217 
6x52 HSD299 HSE218  HSD299 HSE199 HSE218 
6x54  TYR220    TYR220 
6x55 VAL302 VAL221  VAL302 VAL202 VAL221 
6x58  LYS224  LYS305 LYS205 LYS224 
E3      GLU231 
7X34 TRP320 TRP239 TRP220 TRP320 TRP220 TRP239 
7X37 CYS323 CYS242 CYS223     
7x38 ILE324 ILE243 ILE224 ILE324 ILE224 ILE243 
7x41    GLY327    
7x42 TYR328 TYR247  TYR328 TYR228 TYR247 
7x46   SER231     
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2.3.6 Receptors secondary structures data. G2 maintains the partial TM1, the 
hairpin at extracellular loop2 of 7TM and G1 lost the hairpin when binding with 
morphine.  To investigate the secondary structure of the receptors, the abundance over 
the trajectory is shown in (Figure 6). In the six complexes, 0TM helices maintains and 
subtle differences are identified. Notable features are as follows: A). the partial TM1 of 
G2 maintained in the two complexes with morphine and IBNtxA. B). Morphine-G2 
complex showed a 4.02 % β-strand component compared to negligible values in case of 
G1 and wild type receptors, indicating the unfolding of the hairpin at the extracellular 
loop2 in these two systems. IBNtxA binding to its wild type and other two splice variants 
showed three closely related SS components with an average of 4.1%. C). For Morphine-
G1 complex, a part of TM2 and TM6 is unfolded. These structural changes can contribute 
to the loss of activation by morphine on G1 receptor.   D). For IBNtxA, the helical 
content at the intracellular loop 2 are different for the the receptors, in the order of 
G2>G1>7TM. For IBNtxA, the coil content at the intracellular loop3 are different for the 
three receptors, in the order of G1>G2>7TM.  
 
 
 
28 
 
Figure 6. Protein Secondary structure profile of three receptors complexes with Morphine 
(A) and IBNtxA. (B). 
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2.3.7 Receptors dynamic responses for the same ligand. Receptor protein Cα 
Root Mean Square Fluctuation (RMSF) values are shown in (Figure 7 A and B) for the 
Morphine and IBNtxA with G1 and 7TM complexes. We observe the general trend that 
the most rigid parts of the receptor (i.e. helices) exhibit lower RMSF values while loose 
structures such as the N and C terminals and intra and extra cellular loops show high 
RMSF values. In addition, subtle differences are identified for the different receptors in 
complex with the same ligand, these differences mainly located at the flexible part of the 
receptors.  Given the different biological responses of the different receptors in response 
to the same stimulating ligand, these dynamic differences could contribute the different 
biological responses by modulating the interaction between the receptor and down-stream 
signal transduction proteins such as G-protein and or β-arrestin. Being major players in 
signal transduction, both the intracellular loop 3 and extracellular loop 2 receptor 
conformational changes were further scrutinized and compared. For the morphine-
receptor complexes, intracellular loop 3 fluctuation intensities of three receptors were in 
the following order: G1>7TM; and similar order was observed for extracellular loop 2 
fluctuation. 
For the IBNtxA-receptor complexes, the intracellular loop 3 fluctuation intensities of the 
three receptors were in the following order: 7TM>G1; and similar order observed for 
extracellular loop 2 fluctuation.  It appears that the lower the fluctuations are correlated 
with the receptor activation by morphine and IBNtxA.  
We also inspect the different dynamic responses of the same receptor by the two 
different ligands in (Figure 8A and B). Where 7TM shows similar response to both 
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morphine and IBNtxA, G1 have larger fluctuation when binding with morphine than that 
with IBNtxA.  
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Figure 7. RMSF diagrams of receptor Protein C-α. Diagram (A): Morphine-7tm-G1 
protein C-α RMSFs comparison. Diagram (B): IBNtxA-7TM-G1 protein C-α RMSFs 
comparison. The residue index is shown for the full-length wilt type MOR-1 receptor. In 
case of G1 receptor, the RMSF diagram starts at the TM2 skipping TM1 as result of 
truncation. 
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Figure 8. RMSF diagrams of receptor Protein C-α. Figures (A), (B) represent 7TM and 
G1 Receptors Interaction with both IBNtxA and Morphine Comparisons. Each receptors 
pairs were aligned using maestro alignment tool. 
 
 
 
 
2.3.8 Ligand fluctuation (L-RMSF). When the same ligand binds to different 
receptors, its conformation dynamics might be different. To investigate this, the ligand 
RMSFs for morphine and IBNtxA are shown in (Figure 9). Interestingly, the RMSF 
profile of Morphine in the complex with 7TM significantly differs that with G1 and G2, 
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and the RMSF profiles of morphine with G1 and G2 are very similar. Likewise, IBNtxA 
L-RMSF plots differs between 7TM and both G1 and G2, and was similar for G1 and G2.    
 
 
 
Figure 9. Ligand RMSF diagrams of Morphine binding to three different receptors. 
 
 
 
 
 
 
2.4 Discussion and Conclusion 
The compelling side effects and rising addiction rates of current opioids such as 
morphine necessitates more research to explore novel morphine replacement and μ-
opioid receptors. Recent genetic study (62)has shown that the MOR-1 gene has 
alternative splicing leading to alternative 6TM receptors that lacks of TM1, including G1 
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and G2 and Mu3. Furthermore, recent in vivo studies (63) supports the pharmacological 
potency of synthetic Morphine analogue (IBNtxA) on mice 6TM alternatives. According 
to the mouse knockout model (64)Morphine analgesia is lost in exon 1 knock out model 
but reserved in exon 11 knockout. However, IBNtxA analgesia is retained in exon 1 
knockout model and lost in exon 11 knockout. Therefore, the study on the structural, 
dynamics and interaction with ligand of 6TM will greatly advance IBNtxA analgesia. 
Although the crystal structures of 7TM with ligands are available, the high-resolution 
structures of 6TM with ligands are not available.  A recent MD study have been recently 
performed on human Mu receptor wild type and G1 receptor in complex with morphine 
previously (65)While this study provided crucial information about the dynamics of the 
intracellular loop 3 in both G1 and wild type Mu receptors, other structural and dynamic 
differences were not illuminated. Additionally, the G2 receptor characteristic and IBNtxA 
binding properties was not explored previously.  In this study, we probe the dynamic and 
structural properties of G1, G2 and 7TM in complex with morphine and IBNtxA. 
Because the interaction between morphine and 7TM has been widely studied 
experimentally and computationally. We want to validate our results on the morphine-
7TM complex against several early studies.  Most recently, resolved crystal structure of 
murine receptor in complex with BU72 is coincided with our most abundant structure 
after doing alignment with human sequence equivalents. Being a small and compacted 
molecule, morphine could adopt different binding poses within the pocket; however, the 
key residues involved in our binding pose have been consistent with most of previous 
experimental and theoretical studies. For example, the most important interaction 
observed in early studies (66-69) was a salt bridge formed between morphine’s cationic 
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moiety (the tertiary amine) with ASP147 of mouse which corresponds to (ASP149) in 
human MOR-1. Our model confirms that morphine’s cationic moiety is interacting with 
the ASP149 in Human 7TM MOR-1 receptor. A second important interaction was 
hydrophobic interaction between the phenyl group of morphine with TYR298 and TYR 
328 which is also consistent with previous experiments which reported TYR299 and 
TYR326 of mouse MOR-1 as interacting residues(69-71). Another important interaction 
was observed between the aromatic ring of morphine with the sidechain of ILE324 and 
ILE298, which was also consistent with most of the previous studies (68,70,72). Most of 
the residues contacting morphine molecule (including the most crucial residue ASP 149) 
from our study are consistent with previous experimental and computational studies (73-
76). 
Interestingly, these important interactions are not observed in our binding pose between 
morphine to hMOR-1G1. Therefore, the change of the binding pose might contribute to 
the loss of analgesia on the 6TM variants in the exon 11 knockout model. Similarly, the 
residues of hMOR-1 interacting with IBNtxA are quite different from the residues of 
hMOR-1G1 interacting with IBNtxA. Again, these differences might contribute to the 
loss of analgesia of IBNtxA on hMOR-1G1. Interestingly, the salt bridge between 
ASP149 and the cationic moiety of IBNtxA is retained for hMOR-1 and hMOR-1G1. 
This interaction might be necessary for activating the receptor. Those detailed 
interactions can help us design point mutations to decipher the interaction mechanism 
using experimental techniques in the future.  
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Our homology modeling indicated that G1 is completely missing the first TM1 while G2 
is only partially truncated possessing extra 20 amino acids in N terminal region of protein 
(Fig 2). This raised interesting questions on whether the partial TM1 helix is stable, 
whether it cause G2 significantly different from G1 and 7TM in term of receptor 
activation. Our simulation data indicates this partial helix of TM1 of G2 is stable in the 
two simulations in complex with morphine and IBNtxA (Figure S13).   Our energetic, 
structural and dynamic data strongly support G2 are different from 7TM and G1. First, 
our MMGBSA binding data indicates that G2 binding to morphine is weaker than 7TM 
by 7.2 kcal/mol but is stronger than G1 by 11.5 kcal/mol. When binding to IBNtxA, G2 is 
weaker than both 7TM and G1 by 16.4 kcal/mol and 32.3 kcal/mol, respectively. 
Therefore, G2 might not be activated potently by both morphine and IBNtxA. The former 
is support by the fact morphine do not activate 6TM variants. The latter requires further 
testing of IBNtxA on G2 separately rather than the 6TM mixtures in the original test (64). 
Second, our clustering data show the binding pose of morphine and IBNtxA on G2 is 
slightly different on 7TM and G1 (Figure 5 and 6). Third, our secondary structure data 
show that G2-morphine complex maintained the hairpin at the extracellular loop 2, while 
7TM and G1 did not (Figure 7). For G2-IBNtxA complex, its intracellular loop 2 has 
slightly higher helical content than G1 and 7TM.  Fourth, our protein Ca-RMSF data 
show that the G2 profile with morphine and IBNtxA differs significantly from G1 at the 
intra-cellar loops 2 and 3, and the extracellular loop 2 (Figure 8). Because these parts are 
critical in the signal transduction, different RMSF profiles may suggest different receptor 
activation profiles.  
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Figure 10. A schematic detailed atom interaction with protein residues Comparison. 
Interactions that persists more than 30% of simulation time are shown. 
 
38 
 
To understand the significant differences between 7TM and G1 in terms of ligand 
activation, and pharmacological actions, we performed both receptor and ligand based 
comparisons. Our MMGBSA binding data shows that IBNtxA binding affinity to G1 is 
significantly higher than 7TM; this is consistent with the in vivo data that IBNtxA can 
activate G1 in exon 1 knockout model while analgesia is lost in 7Tm, which contain exon 
11 knockout. In contrast, as expected, morphine exhibited higher affinity to its wild type 
compared to G1. Our MD data shows that IBNtxA and Morphine exhibit significantly 
different binding poses as indicated from their most abundant structures (Fig 4). 
Moreover, when we aligned the complexes of the same ligand, it can vividly be seen that 
IBNtxA and Morphine have different binding pose on 7TM and G1 (Table 3). This 
evidence is further reinforced when we examine the 2D interaction profile of each ligand-
receptor complex (Figure 6). Major interactions for morphine on 7TM are observed in 
TM 3 and TM6 which previously suggested to contain the ionic lock responsible for 
GPCR activation(77).However, when interacting with G1, morphine interacted with 
different residues (Figure 5). Likewise, IBNtxA 2D binding profile clearly indicated that 
IBNtxA interface differs significantly between G1 and 7TM receptor. More importantly, 
(Fig 5A) 2D interaction which monitors the highly interacting residues (more than 30% 
of the simulation time) clearly indicates that Morphine was able to make strong 
intermolecular forces with its surrounding lining 7TM pocket .These forces which 
including one pi-pi stacking and two cationic- can be better translated in term of binding 
energies which previously showed that both VDW and lipophilic are two major 
contributing components of the total binding energy Table 2. On the other hand, IBNtxA 
binding to same 7TM receptor was not only showing different residues from different 
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transmembrane, its binding forces were being mostly H-bonds, which might explain why 
it cannot activate this receptor.  
Another important observation from the 2D interaction table is that secondary 
structures (E2) might influence IBNtxA receptor activation particularly in G1 receptors. 
Our MD simulation secondary structure analysis also indicated whereas the hairpin at 
extracellular loop 2 was stable in G1-IBNtxA Complex but was unfolded in 7TM-
morphine complex. This leads us to speculation that this E2 plays important role in 
IBNtxA selectivity and binding .This is consistent with previous experimental studies of 
NMR and mutagenesis which confirmed the crucial role of E2 in ligand allosteric and 
orthostatic activations (78-80).Moreover, our IBNtxA MD trajectories movies clearly 
shows E2 persists as Cantilever umbrella capping the extracellular binding pocket .This 
was true most of the simulation time. This is supported by previous Rhodopsin research 
where N terminus and E2 were folding together forming a lid for ligand binding pocket. 
(63). 
Morphine and IBNtxA induced different receptor responses (Figure 9). This is 
obvious form the pattern of RMSF fluctuations induced by morphine and IBNtxA on 
7TM and G1 receptors. This reinforce our hypothesis that truncation has affected the 
conformational and structural priorities of spliced variants and eventually affected their 
ligand affinities preferences. The suggested mechanism of action of the GPCR including 
the opioids receptors involve the activation of the second and the third intracellular loops 
and the proximal portion of the C terminal(65,74,81). According to our protein Cα RMSF 
data, I3 and I2 loops fluctuations distinctly different in G1 and 7TM. In case of Morphine 
bound G1 receptor, Although I3 loop  was showing   the highest flexibility compared to 
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7TM, it was incapable to influence the cAMP as robust manner as the Morphine effect on 
7TM receptor even at higher doses as indicated by biological tests(65). This paradox is 
attributed to the fact that I3 activation is only one part of the total signal transduction 
pathway in GPCR. It still unclear whether G1 receptor will utilize the classical G-protein 
coupling or the B-arrestin in case of Morphine and IBNtxA. Previous research studies 
revealed that IBNtxA might exert even excitatory effect on G1 splice variant receptor 
contrary to the acknowledged fact of its high efficacy in triple KO mouse(36,65). 
The results of partially or total absence of one transmembrane in wild type GPCR 
scaffold conferred structural and dynamic alterations in receptor capacity to interact 
different ligands .Although the differences between Mu receptors subtypes is subtle 
specially G1 and G2,MD simulation experiments could successfully provide evidence 
that truncated versions G1 and G2 are uniquely different from WT .Moreover, Morphine 
and IBNtxA  preferential affinity toward their WT receptors was obviously noticeable 
from predicted energy calculations.   .This encourages future attempts to design library of 
compounds selective to G1 and/or G2 receptors to achieve high efficacy and lowest side 
effects. 
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Chapter 3 
Computational analysis of Amsacrine resistance in human Topoisomerase II alpha 
mutants (R487K and E571K) using homology modeling and all atom MD simulation 
in explicit membrane 
3.1 Introduction  
Amsacrine is an Acridine derivative and considered as the first topoisomerase II 
inhibitor effective in acute lymphatic leukemia and myeloid leukemia (82).It has 
relatively weak DNA binding affinity of 104 M-1 compared to other intercalates such as 
Adriamycin, Daunorubicin and Actinomycin –D with affinities range between 105-106M-1    
(83)    . Unlike etoposide which inhibit selectively topoisomerase Beta subtype, 
Amsacrine is equally effective in both subtype A and B of Topoisomerase II enzyme 
(84). Amsacrine molecule consists of two moieties; the intercalative Acridine moiety 
attached to 4′-amino-methanesulfon-m-anisidide head group (85) (Figure 11A). While 
intercalative part is important to anchor the molecule between the DNA base pairs, it is 
not sufficient to induce the enzyme inhibitory action by its self without the support of the 
second head group moiety.  On the other hand, the head group have shown be effective in 
stimulating DNA session as standalone molecule without the help of intercalating body. 
Although this was happening at higher concentrations, it clearly indicates Amsacrine 
head group is critically important in its mechanism as inhibitor. (85)  Overall, Amsacrine  
stabilizes  cleavage  complex with DNA via interaction of its head group with top2 
residues (86)  and DNA intercalation (87)Amsacrine intercalation pattern is shown in 
(figure 11C). However, cancer cells can circumvent the inhibitory mechanisms utilizing 
mutations, which ultimately confers resistance (88,89). Previous in vivo studies 
successfully analyzed two important point mutations (R487K and E571K ) in leukemia 
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cell line(90) (Figure 11B). Results conferred Amsacrine Resistance was identified in vivo 
as >100-fold and >25-fold resistance in case of R487K and E571k respectively. Previous 
functional studies had confirmed the reduced cleavable complex formation as resistance 
mechanism  for those two mutants (90). However, none of the previous studies illustrates 
how mutations reduced the stability of the cleavable ligand-DNA-protein complex. In this 
study, we sought to utilize the MD simulation method to study this mutational impact on 
the stability of the cleavable complex of human top2a homolog. We study top2a rather 
than top2b, because top2b is required for normal physiological function and its inhibition 
cause adverse effects (91). We constructed amsacrine-DNA-top2a complex based on the 
previously published crystal structure of top2beta (3Qx3). The wild type complex 
structure was used to introduce two mutants (R487K) and (E571K). The three complexes 
were subjected to 500 ns molecular dynamics simulation for each system. Our MM-
GBSA binding energy calculations indicated a significant weakening of Amsacrine 
affinity toward its wild type compared to two mutants. Our clustering analysis indicates 
the changes of the binding poses upon the two point mutations. In particular, the DNA 
intercalation was completely and partially lost In R487K and E571K mutants structure 
respectively and a ligand was diffused away from its binding site in R487K. Additionally, 
the RMSF results for protein receptors were referring to higher structural and 
conformational changes in mutants protein structures compared with wild type.  
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Figure 11. Structure of Amsacrine (A), amsacrine-Top2α complex (B) and Amsacrine-DNA 
complex(C).  Human Top2α complex model was based on the crystal structure of Top2β (PDB 
id: 3QX3).  Two point mutations that cause drug resistance are indicated in red and yellow 
triangles (B). 
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3.2 Computational Materials and Methods 
3.2.1 Human Topoisomerase IIα structure homology modelling. Crystal 
structure of Human topoisomerase IIβ in complex with etoposide (pdb code 3QX3) (92) 
was used as template to build hTop2α homology model. Prime utility (93,94) 
implemented in Maestro was used to build TOP2A structure homolog based on human 
hTop2α FASTA sequence from Uniprot (43). The final homolog complex structure was 
obtained by docking two prepared Amsacrine molecules into hTop2α using Glide XP 
implemented in Maestro(5,46)  .The complex was prepared using maestro protein 
preparation wizard, optimized and minimized. The same structure was used as primary 
structure of hTopIIα. This structure was used to introduce two mutants (R487K) and 
(E571K) in both A and B chains of hTop2α homolog. 
3.2.2 Molecular dynamic (md) simulations. 
Simulation system setup. All three molecular dynamic simulation systems were 
built using the prepared and refined receptor-ligand complexes from the XP docking as 
input files. In each complex, System was built using SPC as solvent model (48) using 
orthorhombic solvent box .Buffer was used as the method of solvent box size calculation 
.System was neutralized using Na+ ions, and was added with a salt concentration of 0.15 
M NaCl.  After the system was successfully solvated, OPLS3 force field (45) (3) was 
used to represent the receptor-ligand.   
Relaxation and simulation protocols. Desmond simulation package (3) was used 
to run all simulations, systems were first relaxed using the default Desmond relaxation 
protocol. After Simulation for 1.5 ns under the NPT ensemble with no restraints, the 
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relaxed systems were assigned a 400 ns production run conducted under the NPT 
ensemble for each of the three systems using the default protocol.   M-SHAKE (51) was 
applied to constrain all bonds connecting hydrogen atoms, enabling a 2.0 fs time step in 
the simulations. The k-space Gaussian split Ewald method (52) was used to treat long-
range electrostatic interactions under periodic boundary conditions (charge grid spacing 
of ~1.0 Å, and direct sum tolerance of 10–9). The cutoff distance for short-range non-
bonded interactions was 9 Å, with the long-range van der Waals interactions based on a 
uniform density approximation. To reduce the computation, non-bonded forces were 
calculated using an r-RESPA integrator (53) where the short range forces were updated 
every step and the long range forces were updated every three steps. Temperature was 
controlled using the Martyna-Tuckerman-Klein Nosé-Hoover chain-coupling scheme 
with a coupling constant of 1.0 ps. The trajectories were saved at 40.0 ps intervals for 
analysis. All MD simulations were performed under 300 K and 1 bar conditions. 
Molecular dynamic simulations convergence. To explore whether MD 
simulations trajectories were equilibrated toward the end of simulation time, we 
investigated the protein Cα RMSD plots from the raw data for each trajectory (Figure 
S3). Clearly, plots indicate the convergence of Cα RMSD diagram of all three complexes, 
which refers to the state of equilibrium of receptor proteins C alpha at the end of 
simulation time. This indicated a conformational stability of receptor throughout the 
simulation. 
Trajectory clustering analysis.RMSD- based clustering  was used  to group 
Frames from Desmond trajectory (54) implemented  in Schrodinger Software .The 
merging distance cutoff used was 2Å .This tool performs hierarchical clustering on 
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structures from a Desmond trajectory based on the RMSD matrix of a specified set of 
atoms [Schrodinger scripts]. The centroid structure (i.e. the structure having the largest 
number of neighbors in the structural family) was used to represent the family. The 
centroid structures of populated structural families (>1% of total structure population) are 
shown in (Figure S2) of the supporting material. 
3.2.3 Binding energy calculations and decompositions. Binding energies were 
calculated as MMGB-SA using VSGB 2.0 solvation model (4).  Frames from the last 
20ns were used for this purpose .The net free binding energy calculation was performed 
for three complexes: (Ligand +Protein +DNA),( Ligand+ Protein) and (Ligand 
+DNA).For simplicity the previous terms were denoted LDP ,LD and LP respectively .In 
all three calculations , the same number of frames were selected  to get consist binding 
free energy predictions . MM-GBSA calculation procedure consists of energy 
calculations and energy minimizations as follows: Receptor alone (minimization), Ligand 
alone (minimization), Receptor-ligand complex (minimization), Ligand extracted from 
optimized receptor-ligand complex (energy calculation), Receptor extracted from 
optimized receptor-ligand complex (energy calculation).The total binding free energy 
equation is:  
ΔG (bind) = Ecomplex (minimized) - ( Eligand(minimized) + Ereceptor(minimized) ). 
 Decomposition of binding free energy values are also reported in each 
calculation. It includes electrostatic, van der walls, hydrophobic, and composition 
interactions allows for a more detailed understanding of the effect that resistance places 
on each complex.  
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3.3 Results  
Because hTop2a is a homodimer, we were expecting quantitative results from the 
MD simulation to be similar in two chains. However, in most parts, there were 
differences between the two subunits ranging from subtle to significant .Therefore, we 
sought to take the average value of the two chains to simplify the comparison between 
them. 
3.3.1 Amsacrine binding energy calculations. Predicted binding energy of 
Amsacrine indicated significant affinity weakening in two mutants compared to wild type 
hTOP2A.  hTOP2α contains two binding DNA intercalation sites which required two 
separate binding energy  Calculations to investigate the mutational impact on each site 
.The MMGB-SA results are charted in (table 4) . The energy of binding ΔG of WT-LDP 
was calculated to be (-71.81 Kcal/mol) and (-60.93 Kcal/mol) in binding site A and B 
respectively. The E571K mutation impaired LDP binding affinity to be (-42.85 Kcal/mol) 
and (-53.5 Kcal/mol) in site A and B respectively. Moreover, R487K mutation attenuated 
binding affinities of LDP to be (-39.1 Kcal/mol) and (-34.8 Kcal/mol) in sites A and B 
respectively. To get more insight into the mutational impact of ligand on DNA and 
Protein interactions, additional MM-GBSA calculations for LD and LP were performed 
.As can be seen from the (table 4) ,In E571K mutant,the average cost of energy binding 
of  Ligand-protein (LD)  of  was significantly higher than energy needed for Ligand-
protein(LP) interaction (-20.85 Kcal/mol Vs -27 Kcal/mol).   while the opposite was true 
for R487K where Ligand-DNA intercalation required less energy of binding compared to 
ligand –protein interaction (-21.5 Kcal/mol Vs -14.9 Kcal/mol .Another important result 
was gained from the MMGB-SA decomposition of complexes (Table 4) which clearly 
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indicated the significant contribution of both van der Vals forces and Lipophilic terms as 
major component of binding energy for all complexes. While, ΔGBELE contributed less 
favorably to total binding energy magnitude. 
 
 
Table 4 
 Average MM-GBSA binding energies of Amsacrine with hTOP2a WT and Mutants (kcal/mol).  
 
1 ΔG: MM-GBSA binding energy (Complex − Receptor − Ligand). 
2 ΔΔG: Relative binding energy with reference to the WT complex. 
3 ΔVDW: Change of van der Waals energy (vdW + Pi-pi stacking +Self-contact correction) in gas phase      upon complex formation 
4 ΔLIPO: Change of lipophilic term (Lipophilic energy) upon complex formation. 
5ΔGBELE: Change of electrostatic interactions (GB/Generalized Born electrostatic solvation energy+ ELE/Coulomb energy 
+Hydrogen-bonding) upon complex formation. 
LD: Ligand-DNA only Interaction, LP: Ligand-Protein only Interaction, LPD: Ligand-Protein-DNA interaction 
LD: Ligand-DNA complex, LP: Ligand-Protein complex, LPD: Ligand-Protein-DNA complex. 
Note: Binding energy calculated based on average values from two subunits A and B. 
 
 
3.3.2 Amsacrine binding poses and 2D interaction diagram. Two mutants 
adopted different biding pockets and poses compared with wild type. To explore 
mutational impact on Amsacrine binding pose  and ligand interaction  network change , 
WT R487K E571K
ΔG Type LDP LD LP LDP LD LP LDP LD LP
1
ΔG -66.4 -31.9 -32.7 -37.0 -21.5 -14.9 -48.2 -20.9 -27.1
2
ΔΔG 0.0 0.0 0.0 29.4 10.4 17.7 18.2 11.1 5.6
3
ΔVDW -56.3 -33.8 -22.1 -42.5 -27.5 -24.0 -46.4 -27.5 -18.9
ΔΔVDW 0.0 0.0 0.0 13.8 6.3 -1.9 10.0 6.3 3.2
4
ΔLIPO -25.9 -7.9 -17.6 -8.6 -2.2 -6.4 -19.1 -2.7 -16.3
ΔΔLIPO 0.0 0.0 0.0 17.3 5.8 11.2 6.8 5.2 1.3
5
ΔGBELE 15.8 9.8 7.0 14.1 8.2 6.5 17.3 9.4 8.2
ΔΔGBELE 0.0 0.0 0.0 -1.7 -1.6 -0.6 1.4 -0.4 1.1
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we have extracted the most abundant structure of each complex and aligned them  using 
prime implemented in maestro .The three ligands were superimposed according to the 
protein sequence alignments to visualize the nuance differences between the wild type 
and mutants structures. We formulated comparison table of all residues contacting the 
Amsacrine for three different complexes. Obviously, Amsacrine lost most of the 
interacting residues in case of two mutants as seen in (table 5) and sought to bind to 
residues significantly different from the wild type .This was clearly noticeable in R487K 
mutation which exhibited the highest binding affinity weakening .We noticed that 
Amsacrine in chain B in this mutations started forming new interactions in the 400 
residue range of receptor which was absent in case of the wild type. This binding 
deviation was further verified by observing the significant change in binding poses of 
Amsacrine in two mutants (in both binding sites) compared with wild type (Figure 12 
A,B,C,E).   
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Table 5 
 Interacting residues with Amsacrine. 
WT-A WT-B R487K-A R487K-B E571K-A E571K-B
ARG 434
ILE 435
LYS 436 LYS 436 LYS 436
GLY 437
ILE 438
PRO 439
LYS 440 LYS 440
LEU 441
GLH 461 GLH 461 GLH 461 GLH 461 GLH 461
GLY 462
ASP 463 ASP 463 ASP 463 ASP 463 ASP 463
SER 464 SER 464 SER 464 SER 464
PRO 485
LEU 486 LEU 486 LEU 486 LEU 486 LEU 486
ARG 487 ARG 487 ARG 487 ARG 487
LYS 487 LYS 487
GLY 488 GLY 488
LYS 489
ASN 504
ALA 505
GLH 506
GLU 506
LYS 743
TYR 757
HIS 759
GLY 760 GLY 760
GLU 761 GLU 761 GLU 761
MET 762 MET 762 MET 762 MET 762 MET 762 MET 762
SER 763 SER 763 SER 763 SER 763
LEU 764
MET 765 MET 765 MET 765
ILE 766
MET 766 MET  766 MET 766 MET 766
THR 767
MET 769 ILE 769
LYS 798 LYS 798
SER 800 SER 800 SER 800
ALA 801 ALA 801 ALA 801
SER 802 SER 802 SER 802 SER 802 SER 802
PRO 803 PRO 803 PRO 803
ARG 804 ARG 804 ARG 804 ARG 804 ARG 804
TYR 805 TYR 805 TYR 805 TYR 805 TYR 805
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Figure 12.  (A-C) Representatives of the most abundant structure families of the three 
complexes. (D) Superimposition of the three complex structures. (E) Superposition of 
ligand-DNA complexes (WT, E571K and R487K are in green, blue and yellow).   
 
 
 
3.3.3 Amsacrine-DNA intercalation changes. Two mutants exhibited significant 
DNA intercalation changes compared with wild DNA. For each of the simulation system, 
the most abundant structure was extracted using clustering method which group frames of 
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trajectory based on merging distance cutoff (54) .After aligning each representative 
structure of mutants and wild type, we sought to compare the DNA conformational 
changes with respect to Amsacrine in each complex. Results from the two mutants clearly 
shows the loss of intercalation state of Amsacrine partially (in case of E571K and 
completely (in case of R487K) as seen in figure 13 which shows the detailed picture of 
DNA cleavage site.  
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Figure 13. Amsacrine-DNA intercalation Changes of the R487 (B1, B2) and E571K(C) 
Mutations Compared to Wild Type (A).R487K. B1 and B2 represent the front and rear 
views of DNA showing the two-ligand intercalation changes. All three complexes 
represent 3A° cutoff distance from the ligand.  
 
C 
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3.3.4 Enzyme protein Cα RMSF analysis. Enzyme protein Cα RMSF analysis 
indicated significant conformational changes in both mutants compared to wild type 
enzyme. The Root Mean Square Fluctuation (RMSF) is useful for detecting local changes 
along the protein chain. (RMSF) Diagrams of each binding site of the three complexes 
were combined in one diagram for comparison purpose (Figure 14). Results clearly 
shows that for the most part, R487K mutation reflected the highest fluctuation pattern 
compared to E571K mutation, which in turn was higher than WT level (figure 14). This 
clearly indicates the significant conformational changes in protein structure upon 
mutations, which contributes to the weakening effect of the mutation. Furthermore, the 
dominant fluctuation pattern in both binding sites was consist with the secondary 
structure distribution of the enzyme structure where loops and turns are exhibiting the 
highest dynamic effects compared to alpha strands. 
 
 
 
Figure 14. Protein Cα RMSF diagrams of hTop2α WT and mutants upon Amsacrine 
Binding. Residue from 1 to 645 represent the chain (A) of enzyme while residue 646 to 
1330 belongs to chain (B).  
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3.3.5 Ligand conformational change (L-RMSF).Ligand conformational change 
indicated different configurations and higher intensities in two mutants compared to wild 
type.  Ligand RMSF shows the ligands dynamic fluctuations with respect to protein 
broken down by atomic contribution of ligand molecule. It gives insights about the 
entropic contribution endured by the ligand during protein interaction. According to our 
ligand RMSF comparison diagram, the general pattern of fluctuation is significantly 
higher for the mutants compared to the wild type. More importantly, R487K mutant 
showed higher ligand fluctuation than E571K mutant (Figure 15). Another worth 
mentioning is the region of the Amsacrine molecule exhibiting higher fluctuation. 
Obviously, the highest fluctuations are seen in the first and the last part of L-RMSF plot, 
which corresponds, to the 3-methoxy group of m-AMSA and the 4′-amino-
methanesulfon-m-anisidide head group, which are loosely connected groups. However, 
unexpectedly, another high fluctuation was observed at the middle of the plot, which 
correspond, to the third ring of acridine moiety in Amsacrine responsible for active 
intercalation inside DNA grove. 
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Figure 15. Average ligand RMSF for the three complexes. Complexes were aligned and 
superimposed using Maestro software. 
 
 
 
3.4 Discussion and Conclusion  
Previous study identified  two point mutations (R487K and E571K ) of human 
Top2α in leukemia cell line (90). The vivo essays conferred more than 100-fold and 25-
fold resistance to Amsacrine for R487K and E571K respectively. Reduced cleavable 
complex formation was identified to be the resistance mechanism.  However, detailed 
molecular and structural mechanisms underlying this resistance remains to be elusive. We 
have applied homology modeling and MD simulations to mechanically understand 
mutational impact on the complex structure and stability. 
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 Our MM-GBSA binding data indicated the significant weakening  of Amsacrine binding 
affinities toward two mutants compared to wild type as seen in (table 4).The binding 
energy decrease caused by R487K mutation is larger than that by E571K, indicating that 
R487K can cause higher fold of drug resistance than E571K by a bigger reduction of the 
ternary complex formation. This fold change order is consistent with the experimental 
result, which indicated 100 and 25 fold drug resistance for R487K and E571K 
respectively. (95) When decomposing the overall ligand binding into ligand-DNA (LD) 
and ligand-protein (LP) interactions, we observed different contribution pattern for these 
two mutants. In R487K mutation, a ΔΔG value of 17.7 kcal/mol in LP suggested 
significant impairment of ligand interaction with protein TOP2α.  This is likely the direct 
impact of the mutation on the protein’s ability to form intermolecular interaction with 
Amsacrine, because  R487 is one of the major contributors to Amsacrine protein 
interaction in the wild type(86). This also emphasizes  the  role of Amsacrine molecule  
head group in forming the ternary complex (85). On other hand, ΔΔG of LD in R487K 
(i.e. 10.4 kcal/mol) is much lower than change in LP (i.e. 17.7 kcal/mol), indicating that 
ligand-DNA interaction contributes less than ligand-protein interaction to overall ligand 
binding energy decrease. In E571K, decrease of LP (5.6 kcal/mol) is much smaller than 
decrease of LD (11.0 kcal/mol), indicating that change of ligand-DNA interaction plays 
bigger role in the overall decrease of the ligand binding energy. This might be explained 
by the fact that E571K is located far away from the ligand-protein binding site and thus 
cause smaller perturbation on ligand-protein interaction. When comparing R487 with 
E571, the larger LP weakening in R487 is consistent with higher fold resistance 
compared to E571K.  
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Another significant impact of the mutations envisioned through our MD 
simulations were the Amsacrine-DNA intercalation changes as can be seen from the most 
abundant structures of mutants and WT DNA (Figure 13A). For example, the Amsacrine 
Molecule moiety was diffused away  and relocated to be outside the DNA binding groove 
as seen in E571K (figure 13C) . As such, Amsacrine inhibitory effect was lost because 
both intercalating ability and protein binding were abolished and Top2a might be re-
ligated and thus recovered. This agrees the previously published experimental studies that 
established the role of Acridine moiety in Amsacrine to anchor it into the DNA groove. 
(83,85,87)  
The mutations also lead to the changes of ligand-protein binding poses, which can 
be seen in the ligand 2D diagram in (Figure S3) and (Table 5). The most significant 
changes can be observed in R487K chain A and B where protein established new contacts 
with ligands in certain regions while lost some in other regions. Likewise, the binding 
poses comparisons indicated the significant changes in ligand binding pose with respect 
to protein which clearly can be seen in chain B of WT and two mutants Figure S3. These 
results is consistent with the role of Amsacrine as an  enzyme poison (85) in addition to a 
DNA intercalator.   
The protein RMSF profiles further showed the changes of protein dynamics due to the 
mutations. In both mutants, RMSF diagram fluctuation intensity was higher compared in 
WT enzyme. Although this RMSF profiles from on crystal structure of a lesioned DNA 
with Amsacrine were DNA was pre-nicked with Top2 and cleaved; it clearly shows 
larger fluctuation of mutant protein structure can cause disruption in network of residues 
at Amsacrine binding site as seen in Figure 13. More importantly, the fluctuation was 
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observed higher in R487K than E571k which was higher than WT. This was also 
supported by the RMSF averages which also was in agreement with the previous order. It 
appears that the larger protein fluctuation might be required for the normal function of the 
enzyme. Our data showed the active role of two key residues ARG487 and GLU571 in 
maintaining protein backbone integrity and subsequent propagation of the conformational 
change conferred by these two mutations on protein structure and dynamics (96). 
This phenomenon was further pictured via examining the L-RMSF results, which 
measures ligand configurational changes in respect to receptor. Results were indicating 
the unique pattern and higher magnitude of conformational changes in R487K compared 
to WT and E571K mutant (Figure 15). Moreover, regions in Amsacrine molecule of high 
fluctuation were mainly the 3-methoxy group and the 4′-amino-methanesulfon-m-
anisidide head groups. The fact that these groups are the major contributors in Amsacrine 
binding to protein, a higher fluctuation in these groups can negatively affect the ligand-
protein affinity.  This is in fact another advantage of MD simulation which characterizes 
mutational impact between protein and ligand, since ligand conformational orientation is 
essential for proper binding pose and determines the success of intercalation. 
Computational tools enabled us to understand the how mutations lead to 
resistance through energy calculations and other MD simulation parameters. The two 
mutants resulted in binding affinity weakening of Ligand-DNA-Protein complexes of two 
mutants in consistent manner with the in vivo fold resistance results .More importantly, 
larger drug resistance of R487K than E571K was caused by larger weakening of ligand 
protein interaction which agrees with the established Amsacrine inhibitory mechanism 
which emphasize the crucial role of protein in maintaining ternary complex with ligand. 
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For both mutants, weakening of ligand- DNA interaction also contributed to 
destabilization of the ternary complex, a ligand moved out of intercalation was observed 
in R487K and E571K could destabilize the ternary complex due to intercalation loss.  
Furthermore, MD simulation method could detect the significant changes in binding 
poses and 2D interaction diagrams, which also contributed to resistance .MD simulation, 
could prioritizes and characterizes the most significant mutation quantitatively and 
qualitatively. This is crucial for future drug design of effective ligands to counteract these 
mutations. (97) 
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Appendix A 
Supporting Material (Chapter 2) 
Table S1  
Glide XP docking score (units: kcal/mol). 
  hMOR-1 hMOR-G2 hMOR-G1 
Morphine -3.4 -2.7 -3.0 
IBNtxA -3.3 -4.1 -5.4 
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Figure S1. Sequences of full-length and truncated variants of human MOR-1 (hMOR-1). 
Rectangular boxes refer to the Trans membranes helices. The yellow highlight represents 
the amino acids sequences for each transmembrane domain. The intracellular (I1-I3) and 
extracellular loops (E1-E3) connecting the Trans membranes are illustrated as threads 
labeled according to loop location. 
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Figure S2. 3D-structures of morphine, IBNtxA, and their complexes with 7TM, G2 and 
G1 hMOR-1 receptors obtained from Glide XP docking. TM1 is colored in purple. 
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Figure S3. Root Mean Square Deviation (RMSD) of protein-Ligand complexes against 
simulation time. Cα-RMSD is measured using the initial frame as reference, while the 
ligand fit on protein RMSD refer to in place RMSD of ligand when protein is aligned.  
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Figure s4. MMGBSA binding energies of both Morphine and IBNtxA complexes with 
three different receptors. The above columns represent the different components of MM-
GBSA binding energy (kcal/mol).  
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Figure S5. Representative receptor-morphine structures of top structural families from the 
clustering analysis. Abundance is annotated. For all structures, the extracellular and 
intracellular loops were truncated for clarity. The abundance is annotated. 
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Figure S6. Representative receptor-IBNtxA structures of top  Complexes structural 
families from the clustering analysis. Abundance is annotated. 
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Figure S7. Contacts of Morphine to wild type receptor (hMOR-1). The genetic numbering 
is annotated for each interacting residue. A: Interactions fraction over the MD trajectory. 
B: Illustrates interactions persist more than 30% of simulation time. C: The ligand protein 
contacts over the MD trajectory.  
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Figure S8. 2D profile data of Morphine binding with G2 splice variant receptor  
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Figure S9. 2D profile data of Morphine binding with G1 splice variant receptor  
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Figure S10. 2D profile data of IBNtxA binding to wild type receptor (MOR-1). 
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Figure S11. 2D profile data of IBNtxA with G2 splice variant receptor. 
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Figure S12. 2D profile data of IBNtxA with G1 splice variant receptor  
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Figure S14. Secondary structure elements over the simulation time for IbntxA with three 
receptors.  
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Figure S15. Figure S. RMSF diagrams of receptor Protein C-α. Diagram (A): Morphine-
7tm-G2-G1 protein C-α RMSFs comparisons. Diagram (B): IBNtxA-7TM-G1-G2 protein 
C-α RMSFs comparisons. The residue index is shown for the full length wilt type MOR-1 
receptor .In case of G1 receptor, the RMSF diagram starts at the TM2 skipping TM1 as 
result of truncation. 
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Figure S16. RMSF diagram of receptor Protein C-α .Figures G2 Receptor Interaction with 
both IBNtxA and Morphine Comparisons.  
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Figure S17. Ligand torsion profile of Morphine binding to three different receptors. 
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Figure S18. Ligand torsion profile of IBNtxA when biding to three different receptors. 
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Figure S19. Comparison of Morphine-WT Mu receptor (from our experiment) with the 
most recent crystal structure (5CM1) 
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Appendix B 
Supporting Material (Chapter 3) 
Table S1 
 MM-GBSA binding energies of Amsacrine to hTop2α WT and two mutants. 
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Table S2 
 Decomposition of MM-GBSA binding energies of Amsacrine to hTop2α WT and two mutants   
ΔG Type LDP-A LD-A LP-A LDP-B LD-B LP-B LDP-A LD-A LP-A LDP-B LD-B LP-B LDP-A LD-A LP-A LDP-B LD-B LP-B
1
ΔG -71.81 -36.7 -32.7 -60.93 -27.2 -32.6 -39.13 -24 -15.1 -34.82 -19 -14.8 -42.85 -21 -22 -53.5 -20.7 -32.2
2
ΔΔG 0 0 0 0 0 0 32.68 12.73 17.67 26.11 8.16 17.78 28.96 15.73 10.75 7.44 6.42 0.44
3
ΔVDW -60.46 -37.6 -22.4 -52.23 -30.1 -21.9 -51.14 -33.1 -18.1 -33.89 -22 -11.9 -44.11 -28.6 -15.6 -48.68 -26.5 -22.3
ΔΔVDW 0 0 0 0 0 0 9.32 4.51 4.34 18.34 8.11 9.94 16.35 8.98 6.85 3.55 3.6 -0.39
4
ΔLIPO -25.53 -8.59 -16.5 -26.18 -7.28 -18.6 -5.57 -0.89 -4.67 -11.54 -3.41 -8.13 -16.25 -2.58 -13.7 -21.86 -2.91 -18.9
ΔΔLIPO 0 0 0 0 0 0 19.96 7.7 11.8 14.64 3.87 10.5 9.28 6.01 2.81 4.32 4.37 -0.31
5
ΔGBELE 14.18 9.4 6.16 17.49 10.21 7.89 17.57 9.963 7.68 10.61 6.4 5.24 17.51 10.18 7.25 17.05 8.66 9.05
ΔΔGBELE 0 0 0 0 0 0 3.39 0.563 1.52 -6.88 -3.81 -2.65 3.33 0.78 1.09 -0.44 -1.55 1.16
R487KWT E571K
1 ΔG: MM-GBSA binding energy (Complex − Receptor − Ligand). 
2 ΔΔG: relative binding energy with reference to WT complex. 
3 ΔVDW: Change of van der Waals energy (vdW + Pi-pi stacking +Self-contact correction) in gas phase upon complex formation 
4 ΔLIPO: Change of lipophilic term (Lipophilic energy) upon complex formation. 
5ΔGBELE: Change of electrostatic interactions (GB/Generalized Born electrostatic solvation energy+ ELE/Coulomb energy 
+Hydrogen-bonding) upon complex formation. 
LD: Ligand-DNA only Interaction, LP: Ligand-Protein only Interaction, LPD: Ligand-Protein-DNA interaction 
A&B: refers to the two binding sites. 
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Figure S1. Root Mean Square Deviation (RMSD) of Amsacrine-Enzyme complexes 
against simulation time. Cα-RMSD is measured using the initial frame as reference, 
while the ligand fit on protein RMSD refer to in place RMSD of ligand when protein is 
aligned.   
92 
 
 
 Figure S2. Representative hTOP2α-Amsacrine structures of top structural families from 
the clustering analysis. Abundance is annotated. 
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Figure S3. 2D interaction diagrams of Amsacrine with hTOP2α WT and mutants. All 
complexes were aligned and superimposed using Maestro software. 
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Figure S4. 2D profile data of Amsacrine binding to WT hTop2α Chain A.                    
(A) Interactions occurring more than 30% of simulation time. (B) protein interactions 
with ligands throughout simulation time. (C) Timeline representations of interactions and 
contacts. 
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Figure S5. 2D profile data of Amsacrine binding to WT hTop2α Chain B.                    
(A) interactions occurring more than 30% of simulation time. (B) protein interactions 
with ligands throughout simulation time. (C) Timeline representations of interactions and 
contacts. 
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Figure S6. 2D profile data of Amsacrine binding to R487K mutant Chain A. (A) 
interactions occurring more than 30% of simulation time. (B) protein interactions with 
ligands throughout simulation time. (C) timeline representations of interactions and 
contacts. 
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Figure S7. 2D profile data of Amsacrine binding to R487K mutant Chain B. (A) 
interactions occurring more than 30% of simulation time. (B) protein interactions with 
ligands throughout simulation time. (C) Timeline representations of interactions and 
contacts. 
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Figure S8. 2D profile data of Amsacrine binding to E571K Chain A. (A) interactions 
occurring more than 30% of simulation time. (B) protein interactions with ligands 
throughout simulation time. (C) timeline representations of interactions and contacts. 
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Figure S9. 2D profile data of Amsacrine binding to E571K Chain B. (A) interactions 
occurring more than 30% of simulation time. (B) protein interactions with ligands 
throughout simulation time. (C) timeline representations of interactions and contacts. 
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Figure S10. RMSF of hTop2α  WT and mutants in the complex with Amsacrine. Chain 
A sequence is: 0 - 678 .Chain B sequence is: 679 -1361.  
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Figure S11. Ligand RMSF for the three complexes. 
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Figure S12. The secondary structure elements over the simulation time for the three 
complexes. All three complexes were aligned with Maestro software. 
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Figure S13. Ligand torsion profile of Amsacrine when binding to chain A of hTop2α WT 
and mutants.   
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Figure S14. Ligand torsion profile of Amsacrine when binding to chain B of hTop2α WT 
and mutants.  
 
 
